Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 70Neoplasms 47Carcinoma, Non-Small-Cell Lung 26Colorectal Neoplasms 20Neoplasm Metastasis 15Multiple Myeloma 14Thyroid Neoplasms 12Glioma 12Pancreatic Neoplasms 11Hematologic Neoplasms 10Thyroid Carcinoma, Anaplastic 9Brain Neoplasms 8Lung Neoplasms 7Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Neurofibromatosis 1 5Lymphoma 5Leukemia, Myeloid, Acute 5Colonic Neoplasms 5Breast Neoplasms 5Astrocytoma 5Thyroid Cancer, Papillary 4Prostatic Neoplasms 4Neurofibroma, Plexiform 4Glioblastoma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uveal Melanoma 3Skin Neoplasms 3Recurrence 3

Interventions

ispinesib 2trifluridine tipiracil drug combination 1trametinib 1tipiracil 1irinotecan sucrosofate 1Vincristine 1Trifluridine 1Temozolomide 1TP protocol 1SB 743921 1Pemetrexed 1Paclitaxel 1PE regimen 1Interleukin-18 1Immunotherapy 1Imatinib Mesylate 1Exercise Therapy 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumor Cancer × trametinib × Clear all
NCT06962254 2025-05-08

Imatinib and Trametinib for KRAS-mutated Solid Tumor

China Medical University Hospital

Phase 1 Recruiting
10 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡